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The estimation of pathogenicity and penetrance of novel prion protein gene (PRNP) variants presents
signiﬁcant challenges, particularly in the absence of family history, which precludes the application of
Mendelian segregation. Moreover, the ambiguities of prion disease pathophysiology renders conven-
tional in silico predictions inconclusive. Here, we describe 2 patients with rapid cognitive decline pro-
gressing to akinetic mutism and death within 10 weeks of symptom onset, both of whom possessed the
novel T201S variant in PRNP. Clinically, both satisﬁed diagnostic criteria for probable sporadic
Creutzfeldt-Jakob disease and in one, the diagnosis was conﬁrmed by neuropathology. While compu-
tational analyses predicted that T201S was possibly deleterious, molecular strain typing, prion protein
structural considerations, and calculations leveraging large-scale population data (gnomAD) indicate that
T201S is at best either of low penetrance or nonpathogenic. Thus, we illustrate the utility of harnessing
multiple lines of prion diseaseespeciﬁc evidence in the evaluation of the T201S variant, which may be
similarly applied to assess other novel variants in PRNP.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Prion diseases are transmissible, fatal neurodegenerative
conditions affecting humans and animals (Collinge, 2001). The in-
fectious agent is composed of assemblies of abnormally folded
host-encoded prion protein (PrP), some of which acquire protease
resistance, designated as PrPSc (Prusiner, 1998). Human prion dis-
eases most commonly occur sporadically but can be acquired
through dietary exposure or iatrogenesis. Inherited prion diseases
(IPDs) comprise 10%e15% of the total annual incidence and are
associated with coding mutations in the prion protein gene (PRNP)
(Mead, 2006). Clinical phenotypes of IPD are highly heterogeneousInstitute of Prion Diseases,
244.
Inc. This is an open access articleand include rapidly progressive forms of dementia and/or ataxia
(indistinguishable from sporadic Creutzfeldt-Jakob disease [CJD]),
fatal familial insomnia and more slowly progressive syndromes
such as Gerstmann-Straussler-Scheinker disease and PrP systemic
amyloidosis (Mead and Reilly, 2015; Mead et al., 2013).
A great deal is now known about normal variation of PRNP in
different populations (Beck et al., 2010; Minikel et al., 2016). Situated
on one end of the spectrum are commonly occurring benign poly-
morphisms, some of which can modify prion disease susceptibility
and clinical phenotype, while on the other lies well-deﬁned highly
penetrant variants such as the P102L, E200K, D178N, and large octa-
peptide repeat insertions. Then there are partially penetrant variants
such as V210I found both in control and patient populations that are
associated with increased risk but not inevitable disease (Minikel
et al., 2016). The advent of low-cost, high-throughput genomic
sequencing technologies has led to large-scale population genomicunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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used recently led to reclassifying several PRNP sequence variants,
previously reported to be pathogenic in the literature, as likely to be
either low risk or even benign (Minikel et al., 2016).
The most challenging ones to classify are the extremely rare
variants found in only a few patients and controls. Causal analyses
of these rare PRNP variants seen in CJD, particularly in the absence
of family history, have historically been biased toward overcalling of
pathogenicity (Minikel et al., 2016). Erroneous assignation of
pathogenicity and penetrance to a benign variant may not only lead
to unnecessary psychological distress but could also misdirect ge-
netic counseling for the patients’ relatives. At the research level,
analysis of sets of variants classiﬁed as accurately as possible by
pathogenicity may help uncover fundamental mechanisms of prion
disease. Here, we illustrate our practice in estimation of the cau-
sality of the novel PRNP variant T201S. We used multiple lines of
evidence and address the challenges faced with interpretation of
rare gene variants that may be applicable to other PRNP variants
and those in genes related to other neurodegenerative diseases.
2. Methods
2.1. Neuropathology
Formalin-ﬁxed and formic acid pretreated parafﬁn-embedded
postmortem brain tissue samples were available from case 1. Tis-
sue sections from the neocortex, hippocampus, deep gray nuclei,
brain stem, and cerebellum were routinely stained with hematox-
ylin and eosin and PrP immunohistochemistry (anti-PrP antibodies
ICSM35, D-Gen Ltd, London, UK, 1:1000 and KG9, University of
Edinburgh, 1:500) with Ventana (Roche) automated staining in-
struments following the manufacturer’s guidelines, using bio-
tinylated secondary antibodies and a horseradish
peroxidaseeconjugated streptavidin complex and dia-
minobenzidine as a chromogen.
2.2. Immunoblotting and molecular genetic and strain typing
All procedures were carried out in a microbiological contain-
ment level III facility with strict adherence to safety protocols.
Frozen brain (gray matter from frontal cortex) of case 1 was pre-
pared as a 10% (w/v) homogenate in Dulbecco’s sterile phosphate-
buffered saline lacking Ca2þ and Mg2þ ions using a tissue grinder
as described previously (Wadsworth et al., 2008). The brain ho-
mogenate was analyzed with and without proteinase K digestion
(50 mg/mL ﬁnal protease concentration, 1 hour, 37 C) by immu-
noblotting with anti-PrP monoclonal antibody 3F4 using high-
sensitivity enhanced chemiluminescence as described previously
(Wadsworth et al., 2001, 2008). Molecular strain typing of PrPSc was
performed by comparison to reference cases of sporadic CJD (sCJD)
and IPD of known PrPSc type (Hill et al., 2006, 2003). For quanti-
tation and analysis of PrPSc glycoform ratios, blots were developed
in chemiﬂuorescent substrate (AttoPhos; Promega) and visualized
on a Storm 840 phosphorimager (Molecular Dynamics). Quantita-
tion of PrPSc glycoforms was performed using ImageQuaNT soft-
ware (Molecular Dynamics) (Hill et al., 2003, 2006; Wadsworth
et al., 2008). Gene analysis was done as previously described
(Wadsworth et al., 2008).
3. Results
3.1. Case 1
A 63-year-old right-handed Danish Caucasian lady, with no
previous medical illnesses or family history of neurodegenerativediseases, was admitted urgently to her local stroke unit with a 5-
day history of abrupt onset ﬂuent dysphasia in October 2009.
Detailed speech examination revealed preserved ﬂuency and
comprehension but markedly impaired repetition, reminiscent of
conduction aphasia. Computed tomography of her brain was un-
remarkable, and she was subsequently discharged with secondary
prevention measures for stroke, after 3 days. Nine days following
hospital discharge, she returned with sudden onset right-sided
paresthesia, and thereafter, her clinical complex evolved rapidly
through a sequence of dysarthria, nonﬂuent speech, dyslexia, dys-
graphia, motor and verbal perseveration, startle, myoclonus, aki-
netic mutism, and ﬁnally death over the period of 10 weeks.
The patient has 2 older sisters, both of whom are alive and well in
their 70s at the present time. Her father died of cancer at the age of 80
years, while her mother lived until the age of 90 years; neither parent
hadneurological or cognitive symptoms in life. The patient’s father had
a sister who died in “old age” of an unknown cause; her mother had 2
other siblingswhodiedof cancer at 63 and73years of age, respectively.
Magnetic resonance imaging (MRI) of her brain revealed
restricted diffusion in her caudate heads, anterior putamina, and
predominantly left-sided cortical ribboning. Her electroencepha-
logram (EEG) showed left frontotemporal slowing of 1e2 Hz, with
occasional sharp waves over the left hemisphere. Her cerebrospinal
ﬂuid had 3 white cells and 308 red cells but normal protein and
glucose levels; protein 14.3.3 was positive, and neuron-speciﬁc
enolase (NSE) was raised 101 ng/ml (<35 ng/mL); real-time
quaking-induced conversion assay was not performed.
3.2. Case 2
A 76-year-old right-handed British Caucasian woman, with no
family history of neurodegenerative diseases, developed abrupt
onset bilateral upper limb postural and action myoclonus. In the
following week, she exhibited unusual sitting postures (axial
apraxia), and her gait assumed a narrow-based shufﬂing character
(gait apraxia). She then developed a rapidly progressive nonﬂuent
dysphasia that rendered her effectively mute within 3 weeks. In
tandem with that, she became socially withdrawn, abulic, and
completely indifferent to her surroundings. Subsequently, she
developed visual hallucinations, exaggerated startle, severe myoc-
lonus, incontinence, and akinetic mutism. She died 8 weeks after
symptom onset; a postmortem examination was not carried out.
The patient was the only child. Her father died of bone cancer at
the age of 73 years, while her mother died of lung cancer at the age
of 57 years.
Her MRI brain showed asymmetrical cortical ribboning with a
left-sided emphasis and bilateral anterior basal ganglia diffusion
restriction, while her EEG showed generalized periodic complexes.
cerebrospinal ﬂuid cell count and routine biochemistry were
normal, but no sample was analyzed for protein 14.3.3, S100B, or
real-time quaking-induced conversion assay.
3.3. PRNP analysis
Sequencing of the open reading frame of the PRNP in both pa-
tients demonstrated a threonine to serine missense substitution at
codon 201 (T201S); the underlying nucleotide change was
c.602C>G (CCDS 13080.1) in both cases. Their codon 129 genotypes
were both methionine homozygous (MM).
3.4. Neuropathology
Routine hematoxylin and eosinestained sections revealed
widespreadmicrovacuolar degeneration in the neocortex, deep gray
nuclei and to a lesser extent in the molecular layer of the cerebellar
T.H. Mok et al. / Neurobiology of Aging 71 (2018) 265.e1e265.e7 265.e3cortex. Immunostaining for abnormal PrP showed diffuse synaptic
(punctate or granular) labeling throughout gray matter regions but
no kuruormulticentric plaques orother plaque-like deposits (Fig.1).
In thewhitematter, therewere no ﬁlamentous deposits, which have
been reported in a proportion of IPD cases (Reiniger et al., 2013). The
histological appearances were indistinguishable from sCJD patients
with PRNP 129MM genotype and type 2 molecular prion strain
[London Classiﬁcation (Hill et al., 2003) corresponding to type 1 of
the Parchi classiﬁcation (Parchi et al., 2009)].Fig. 1. Comparison of prion pathology between T201S patient (case 1) and classical sCJD case
BeB2) is similar to that seen in PRNP 129MM sCJD case (CeC2 and DeD2): Hematoxylin an
cerebellar cortex (A2 and C2) show widespread microvacuolar degeneration in the neurop
ICSM35 antibody (DeD2) show diffuse synaptic (punctate or granular) labeling (B and D, fron
Abbreviations: MM, methionine homozygous; PrP, prion protein; sCJD, sporadic Creutzfeldt3.5. Molecular strain typing
Immunoblot analyses of brain homogenate from T201S case 1
demonstrated a PrPSc type corresponding to type 2 PrPSc of the Lon-
don classiﬁcation seen inpatientswith sCJD (Hill et al., 2003) (Fig. 2A).
Type 2 PrPSc shows a predominance of monoglycosylated PrP (Hill
et al., 2003), which contrasts markedly with the distinctive glyco-
formratioofmutantPrPSc seen in IPDE200K(Fig.2B) (Hill et al., 2006).
These ﬁndings indicate that the T201S missense coding change does, both with PRNP codon 129MM genotype. Prion pathology in T201S patient (AeA2 and
d eosinestained sections from the frontal cortex (A and C), putamen (A1 and C1), and
il. The same regions immunostained for abnormal PrP with KG9 antibody (BeB2) and
tal cortex), (B1 and D1, putamen), and (B2 and D2, cerebellar cortex). Scale bar: 100 mm.
-Jakob disease.
Fig. 2. PrPSc typing in T201S patient brain. (A) Immunoblot of proteinase Kedigested 10% (w/v) brain homogenates (frontal cortex) from T201S case 1 and reference cases of sCJD or
IPD E200K using anti-PrP monoclonal antibody 3F4 and high-sensitivity enhanced chemiluminescence. The provenance of the brain sample is designated above each lane and the
PrPSc type (London classiﬁcation [Hill et al., 2006, 2003]) and PRNP codon 129 genotype of the patient (M, methionine, V, valine) are shown below. (B) Ratios of the 3 principal
protease-resistant PrP glycoforms seen in PrPSc from T201S case 1 in comparison to PrPSc from patients with classical CJD or IPD E200K. Data points for the reference cases represent
the mean relative proportions of diglycosylated, monoglycosylated, and unglycosylated PrP as percentage  standard error of measurement. In some cases the error bars were
smaller than the symbols used. The number of reference cases analyzed were sCJD 129MM with type 2 PrPSc (n ¼ 37), sCJD 129MV with type 2 PrPSc (n ¼ 8), sCJD 129VV with type 2
PrPSc (n ¼ 9), and IPD E200K (n ¼ 6; three 129MM with type 1 PrPSc fragment size, two 129MV with type 2 PrPSc fragment size and 1 129VV with type 3 PrPSc fragment size).
Abbreviations: CJD, Creutzfeldt-Jakob disease; PrP, prion protein; PK, proteinase K; sCJD, sporadic CJD.
T.H. Mok et al. / Neurobiology of Aging 71 (2018) 265.e1e265.e7265.e4not impart conformational preferences to PrPSc in the sameway that
E200K does (Hill et al., 2006), (Asante et al., 2009).
3.6. Effect of T201S on prion protein structure
The threonine to serine substitution studied here is also con-
servative, as both these amino acids are uncharged, polar, and of
similar size; serine being slightly smaller due to the substitution of
a proton for the methyl group found in the threonine side chain.
Furthermore, X-ray and nuclear magnetic resonance studies of re-
combinant PrPC(Antonyuk et al., 2009; Biljan et al., 2013) show that
T201 is situated at the start of helix 3 of the PrP, with its side chain
predominantly solvent exposed rather thanwithin the protein core;
thus, unlikely to destabilize PrPC (Fig. 3).
3.7. Computational (in silico) predictions
A range of sequence- and structure-based in silico tools is
available to assist the interpretation of novel missense variants. It is
however recognized that these computational algorithms are in-
clined to overestimate the damaging effect of missense variants,
particularly in the context of variants of milder impact.
Here, Polymorphism Phenotyping version 2 (PolyPhen-2)
(Adzhubei et al., 2013) and Sorting Intolerant From Tolerant (SIFT)
(Kumar et al., 2009) predicted that the T201S mutation to be
possibly damaging or deleterious, respectively; its Combined Anno-
tation Dependent Depletion (CADD) (Kircher et al., 2014) score of 26
ranks it within 1% of the most deleterious mutations.While these in
silico tools are unanimous in their predictions for highly penetrant
mutations such as P102L, D178N, and E200K (probably damaging by
PolyPhen-2, deleterious by SIFT, and score >30 by CADD), pre-
dictions for other PRNP missense variants, both benign and path-
ogenic, are somewhat mixed. For example, the benign V209M is
predicted to be benign by PolyPhen-2, deleterious by SIFT, and aCADD score of 20.2; the incompletely penetrant V210I is predicted
to be benign by PolyPhen-2, tolerated by SIFT, and a CADD score of
13.53; the highly penetrant A117V is predicted to be probably
damaging by PolyPhen-2 and CADD score 23.3, but tolerated by SIFT.
Hence, this illustrates why sequence variants of PRNP should not be
evaluated solely by in silico tools.
3.8. Estimating the penetrance of T201S
T201S was found in a single individual in the Broad Institute’s
Genome Association Database (gnomAD) (Lek et al., 2016) of
123,125 individuals (1 in 246,250 alleles). By leveraging this large-
scale population database, we then used methods for calculating
the baseline risk of CJD previously described in Minikel et al. (2016)
and computed the upper bound of the 95% conﬁdence interval (CI)
using the Wilson Interval (Minikel et al., 2016). The total CJD alleles
from sequenced PRNP are derived from the sum of alleles in
sequenced CJD cases in Minikel et al. (2016) (years 1990e2013) and
additional alleles (n ¼ 844) from sequenced CJD cases at the
Medical Research Council Prion Unit (years 2014 to present). The
estimated penetrance of T201S using this approach is 0.45% (95% CI
0.02%, 9.35%).
4. Discussion
The clinical picture of IPD caused by highly penetrant PRNP
mutations such as E200K, D178N, and P102L can be indistinguish-
able from that of sCJD. Both our cases had acute clinical onsets
within the peak age range of onset reported for sCJD, followed by
rapid neurological decline and death within 3 months. Together
with restricted diffusion affecting the anterior basal ganglia and
cortical ribboning on MRI, generalized periodic complexes on EEG
(case 2), cerebrospinal ﬂuid protein 14.3.3 positivity (case 1), and
neuropathological ﬁndings (case 1), both these patients fulﬁlled
Fig. 3. Location of the T201S variant in the structure of human PrPC. PrPC is displayed
as a “ribbon” representation of its secondary structure, together with side chain
groups. a-Helices are colored red and b-strands colored cyan (residues 125e225 are
displayed). Residue 201 is located at the start of the third a-helix and is colored in blue
with its threonine side chain displayed in stick representation. This ﬁgure was pre-
pared using PyMOL (PyMOL Molecular Graphics System, Schrödinger, LLC). Abbrevia-
tion: PrP, prion protein. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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sequencing not been carried out.
Given that neither case is derived from multiplex families with
affected individuals, principles of Mendelian segregation cannot be
applied to implicate the T201S mutation in causing familial CJD. In
addition, like many rare gene variants, it is not possible to apply
practice guidelines such as the American College of Medical Genetics
and Genomics for novel gene variants (Richards et al., 2015) in the
case of T201S, due to insufﬁcient data to combine criteria for strat-
iﬁcation (Table 1). With T201S in particular, there is lack of segre-
gation, functional, de novo, and computational and predictive data to
satisfy the stipulated American College of Medical Genetics and
Genomics criteria. Moreover, it should be pointed that highly
penetrant PRNP mutations cause disease by unknown mechanisms
that result in a conformational structural change, rather than by
simple loss- or gain-of-functionmechanisms inwhich functional and
computational data can bemore tractable to study in cellularmodels.
Interrogation of PrP structure and its perturbations by missense
mutations have largely focused on stabilization/destabilization of
the native PrP structure. However, these studies using recombinant
PrP show that stabilization/destabilization of the native PrPC
structure is not consistently observed across all known pathogenic
mutations (Liemann and Glockshuber, 1999). Furthermore, obser-
vations made from these models may not be applicable to real life,
as recombinant PrP is unanchored to the cell membrane andunglycosylated, and certainly could fail to capture all of the folding
problems encountered in vivo. Alternatively, the disease-associated
mutations may primarily affect the stability of more relevant on-
pathway folding intermediates (Hart et al., 2009). As such, the
pathogenicity of T201S cannot be completely ruled out based solely
on PrP structural considerations, despite the seemingly minor
perturbation of the native PrPC structure by the T201S substitution.
Nevertheless, we showed that it is possible to produce both
qualitative and quantitative estimates of pathogenicity and pene-
trance for T201S respectively, by harnessing data from multiple
lines of evidence speciﬁc for prion disease. Different prion strains
can propagate in the same host to produce different disease phe-
notypes and appear to be encoded by distinct abnormal PrP con-
formations and assembly states (Collinge, 2016; Collinge and
Clarke, 2007; Prusiner, 1998). Different human PrPSc isoforms
associated with phenotypically distinct forms of human prion dis-
ease (molecular strain types) have considerable diagnostic utility
and are classiﬁed by both the fragment size and ratio of the 3
principal PrP bands seen after protease digestion (Hill et al., 2006,
2003). Variations in the primary sequence of human PrP pro-
foundly affect the ability of the expressed protein to propagate
particular prion strains through conformational selection (Collinge,
1999, 2001, 2016; Collinge and Clarke, 2007; Wadsworth and
Collinge, 2011; Wadsworth et al., 2004, 2010). The codon 129
polymorphism (either methionine or valine) determines the ability
of wild-type human PrP to propagate particular prion strains in
patients with sporadic or acquired forms of prion disease while
highly penetrant missense mutations that cause IPD (Mead, 2006),
for example, P102L, E200K, and D178N, impose additional confor-
mational preferences for PrP assemblies, resulting in PrPSc molec-
ular strain types that are distinct from those propagated in patients
with sporadic or acquired etiologies (Asante et al., 2015, 2009; Hill
et al., 2006; Wadsworth et al., 2010, 2006). Immunoblot and gly-
coform analyses showed that PrPSc from T201S brain tissue
resembled that of type 2 sCJD 129MM rather than that seen in
highly penetrant PRNP point mutations, for example, E200K. This
dissimilarity is further reinforced by the absence of white matter
ﬁlamentous PrP deposits on neuropathology, although it can be
argued that this observation has limited negative predictive value
for variants toward the carboxy-terminal of PRNP (Reiniger et al.,
2013). PrP structural analyses also suggest that the resulting
amino acid substitution is not expected to impart a signiﬁcant
change in PrP conformation.
Finally, we argue that the estimated penetrance of 0.45% (95% CI
0.02%, 9.35%) calculated by leveraging the gnomAD (Lek et al., 2016)
population data indicate that T201S is at most a low-risk gene
variant for CJD. If we arbitrarily consider a central estimate of 10% or
higher as the clinically signiﬁcant threshold at which to refer for
predictive testing, an excess of 44 T201S alleles in the CJD-diseased
population would need to be observed, provided that the other
variables remain constant. It is highly unlikely that new variants
discovered in routine disease surveillance will achieve these counts
in the foreseeable future.
One important factor that determines the accuracy of pene-
trance estimation is ascertainment of the true population allele
count; not only can this be imprecise for singletons of extremely
low frequency (such as T201S) but also biased toward underesti-
mation. Within the Exome Aggregation Consortium and gnomAD
data set, this is exempliﬁed by the shift in calculated penetrance
from 0.22% (95% CI 0.01%, 4.56%) to 0.45% (95% CI 0.02%, 9.35%),
when the original Exome Aggregation Consortium database
expanded into the gnomAD in which the allele count doubled from
121,384 to 246,250 alleles. Even more strikingly, it was pointed out
that 69% of very rare singletons for Europeans (6503 exomes) in the
Exome Sequencing Project were not identiﬁed again in the Exome
Table 1
Lines of evidence used to estimate T201S causality in comparison to ACMG guidelines
Supportive features of variant pathogenicity
ACMG guidelines Pathogenic PRNP variants T201S
Population data Absent in population databases (NB partially penetrant
variants may be rarely detected in large population
samples)
Yes No
Prevalence in affected patients statistically increased
over controls
Yes Yes, but penetrance is
close to zero
Computational data Multiple lines of computational evidence support
a deleterious effect on the gene/gene product
Not always consistent Yes
Novel missense change at an amino acid residue
where a different pathogenic missense change has
been seen before or protein length changing variant
Yes No
Same amino acid change as an established variant Yes No
Predicted null variant in a gene where LOF is a known
mechanism of disease
Not applicable Not applicable
Functional data Missense in gene with low rate of benign missense
variants and pathological missenses common
Rare missense variants
are common in PRNP
Rare missense variants
are common in PRNP
Mutational hotspot or well-studied functional domain
without benign variation
Not applicable Not applicable
Well-established functional studies show
a deleterious effect
No simple functional model No simple functional model
Segregation data Cosegregation with disease in multiple
affected family members
Yes No
De novo data De novo with or without paternity and
maternity conﬁrmed
Yes in some cases Unknown
Allelic data Detected in trans with a pathogenic variant
(recessive only)
Not applicable Not applicable
Other data Patient’s age, phenotype, or family history
highly speciﬁc for gene
Very young onset (<40) makes sCJD less
likely. Sometimes speciﬁc IPD phenotypes,




Filamentous PrP deposition in white matter on
autopsy
Often seen Not seen
Western blot appearances Diglycosylated PrP predominates Monoglycosylated PrP
predominates (similar to sCJD)
Protein structure considerations Protein structure analysis sometimes predicts
destabilization but not consistently.
Protein structure analysis does
not predict destabilization.
Key: ACMG, American College of Medical Genetics and Genomics; IPD, inherited prion diseases; LOF, loss of function; NB, nota bene; PrP, prion protein; sCJD, sporadic
Creutzfeldt-Jakob disease.
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et al., 2016). Hypothetically, if this holds true for gnomAD, the true
allele frequency of a rare singleton such as T201S could be 1 in 2.5
million or lower, raising the upper limit of the 95% CI to 94% (or
higher) and rendering the estimation meaningless. Bearing this in
mind, the mere presence of T201S in large gnomAD database does
not absolve T201S as a highly penetrant variant. However, the late
ages at onset, lack of family history, lack neuropathological features
of IPD, and molecular strain typing (glycoform ratio) reminiscent of
sCJD are all in linewith the estimation that T201S is either benign or
at most a low-risk variant below “clinically signiﬁcant” threshold.5. Conclusion
At present, although we cannot conclusively determine whether
T201S is a nonpathogenic variant co-occurring with sCJD or a low-
risk non-Mendelian variant, its estimated penetrance is insufﬁcient
to justify routine predictive PRNP testing in individuals at risk of
T201S. The results of our analyses were discussed with the family of
case 2, and the above conclusion was conveyed. Nevertheless, her
offspring requested a referral to a clinical geneticist, who arrived at
the same conclusion, and similarly advised against predictive PRNP
testing. We recognize that further research, particularly expanding
the coverage of molecular strain typing to include other PRNP
sequence variants of varying pathogenicity and penetrance, is
required to reﬁne it as a discriminating tool. In addition, future
expansion of large-scale population genomic databases in tandem
with assiduous surveillance and sequencing of PRNP in CJD caseswill further hone the precision of estimating true penetrance of rare
sequence variants.
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